Aggressive prostate cancer (PC) relies on lipid metabolic reprogramming and pathological iron (Fe) accumulation to drive disease progression. While peroxisome proliferator-activated receptor-gamma (PPARγ) is a master regulator of this lipid-addicted phenotype, direct therapeutic targeting remains clinically limited by systemic toxicity. We propose a novel therapeutic framework: the Fe- cyclooxygenase (COX)/lipoxygenase (LOX)- prostaglandins (PGs)/leukotrienes (LTs)-PPARγ signaling axis. This hypothesis identifies intracellular iron bioavailability as the critical catalytic switch for oncogenic PPARγ activity. Within this axis, Fe serves as an essential cofactor for COX and LOX enzymes that synthesize activating eicosanoid ligands, PGs and LTs, required for receptor transactivation. This model shifts the paradigm of iron chelation from traditional nutritional starvation to a sophisticated signal-transduction interference strategy. By deactivating COX/LOX through active-site coordination and peroxide tone modulation, iron chelators e.g., deferoxamine, deferiprone induce a ligand deficit that forces PPARγ into an inactive apo-conformation, silencing pro-survival genes such as FASN and CD36. To validate this axis, we propose a multi-faced roadmap. This involves in vitro rescue experiments confirming that exogenous ligands bypass chelation-induced silencing, paired with in vivo transcriptomic RNA-seq and cistromic ChIP-seq mapping to verify the global attenuation of the PPARγ regulation. This signaling interference model provides a mechanistic rationale for using iron chelators as indirect transcriptional modulators. Such a strategy may provide a precision-guided approach for sensitizing castration-resistant disease to conventional therapeutic regimens.
扫码关注我们
求助内容:
应助结果提醒方式:
